EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Photodynamic therapy of tumors and other diseases using porphyrins


Lasers in Medical Science 2(1): 4-15
Photodynamic therapy of tumors and other diseases using porphyrins
Photodynamic therapy (PDT) with porphyrins and red light (620-630 nm) is finding increasing clinical application for both the eradication of relatively small tumours and the palliation of inoperable or obstructive tumours. PDT also shows some promise for the sterilization of the tumour bed after surgical removal of neoplasmic masses. Several porphyrins have been found to be accumulated and retained by tumour tissues; however, a chemically prepared derivative of haematoporphyrin, termed HpD, and a purified form of HpD, termed DHE (dihaematoporphyrin ether or ester), are most frequently used in clinical practice owing to their optimal tumour-localizing properties and low systemic toxicity in the dark. The efficiency of HpD/DHE photoactivation by red light is very low, since their extinction coefficient at wavelengths above 600 nm is below 103 M-1 cm-1. Therefore, a large number of investigations are being performed in order to improve the efficacy of PDT. One approach involves the use of porphyrin analogs (e.g., chlorins, phthalocyanines) which retain a high affinity for tumours and possess intense absorption bands in the red spectral region. Moreover, the selectivity of tumour targeting can be enhanced by transport of the photosensitizing drug with some types of lipoproteins or monoclonal antibodies. These developments are of interest also in view of the proposed extension of PDT to the treatment of other diseases, including viral and microbial infections, atheroma and psoriasis.

(PDF 0-2 workdays service: $29.90)

Accession: 006110681



Related references

Photodynamic therapy of transplantable n 4 5 nitro 2 furyl 2 thiazolylformamide induced urothelial tumors using reduced porphyrins and light. Abstracts of Papers American Chemical Society 192, 1986

Interactions with glutathione S-transferases of porphyrins used in photodynamic therapy and naturally occurring porphyrins. Biochemical Journal 229(3): 823-831, 1985

Porphyrins and their physicochemical properties in relation to porphyrins use in photodynamic therapy. Federation Proceedings 44(5): 1781, 1985

In vivo fluorescence kinetics and photodynamic therapy efficacy of delta-aminolevulinic acid-induced porphyrins in basal cell carcinomas and actinic keratoses; implications for optimization of photodynamic therapy. European Journal of Dermatology 10(5): 351-356, 2000

Photodynamic effects of various types of porphyrins on cultured hepatocellular carcinoma cells (JTC-16): a fundamental study of porphyrin photodynamic therapy. Nihon Shokakibyo Gakkai Zasshi 82(2): 261-269, 1985

Photodynamic properties of porphyrins photodynamic therapy of cancer. Szantay, C. Chemistry And Biotechnology Of Biologically Active Natural Products; Fourth International Conference, Budapest, Hungary, August 10-14, . Xi 402p. Akademiai Kiado: Budapest, Hungary. Illus. 367-380, 1988

Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochemistry and Photobiology 80: 22-30, 2004

The use of porphyrins in photodynamic therapy. Abstracts of Papers American Chemical Society 206(1-2): AGRO 146, 1993

Photobleaching of porphyrins used in photodynamic therapy. Photochemistry & Photobiology 47(SUPPL): 55S, 1988

Photobleaching of porphyrins used in photodynamic therapy and implications for therapy. Photochemistry & Photobiology 45(4): 501-506, 1987